Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
Status:
Recruiting
Trial end date:
2024-12-03
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, multicenter phase II study aimed at evaluating the
efficacy and safety of Envafolimab combined with standard platinum containing dual drug
chemotherapy and Recombinant Human Endostatin in patients with advanced (stage IIIB-IV)
squamous non-small cell lung cancer.